BeOne Newsroom
Press Releases
Read our latest news.
-
December 23, 2025
Health Canada Approves TEVIMBRA® (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma
-
May 27, 2025
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
-
October 29, 2024
BeiGene Canada Proud National Sponsor of the Leukemia & Lymphoma Society of Canada’s 2024 Light The Night
-
May 8, 2024
Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada
-
February 7, 2024
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
January 31, 2024
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access through public reimbursement to BRUKINSA® (zanubrutinib)
-
May 30, 2023
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adult
-
February 6, 2023
Quebec becomes first province to cover BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s macroglobulinemia
-
January 9, 2023
BeiGene Canada Named a Great Place to Work®
-
April 8, 2021
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia